Previous 10 | Next 10 |
BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“ Genetron Health ” or the “ Company ”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screen...
Genetron ( NASDAQ: GTH ) said it received a preliminary non-binding proposal from its Co-founder, Chairman and CEO Sizhen Wang to acquire the company for US$0.272 per ordinary share or US$1.36 per ADS in cash. Wang intends to fund the proposed transaction via a co...
BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“ Genetron Health ” or the “ Company ”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screeni...
BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products...
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a Science /AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”, which launched tod...
Genetron Holdings (GTH): Q4 Non-GAAP EPS of -$0.02 beats by $0.05; GAAP EPS of -$0.02 beats by $0.04.Revenue of $20.5M beats by $0.36M.FY2021: Revenue to be around RMB615M-RMB625M, representing around 45%-47% growth over 2020.Press Release For further details see: Genetron Holdings EPS ...
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, t...
HCCscreen TM achieved 88% sensitivity and 93% specificity, compared with 71% and 95%, respectively, by ultrasound plus AFP. In early-stage patients, the sensitivities of HCCscreen TM are 85% (tumor size of <3cm) and 96% (3-5 cm). The Company plans to initiat...
Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, ...
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today ann...
News, Short Squeeze, Breakout and More Instantly...
Genetron Holdings Limited Company Name:
GTH Stock Symbol:
NASDAQ Market:
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision onc...
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and c...